Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million TRELEGY year-to-date sales on...